Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06138210
Other study ID # XMEC-2023-004
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 27, 2024
Est. completion date August 30, 2025

Study information

Verified date May 2024
Source Xuanwu Hospital, Beijing
Contact Junwei Hao, MD; PhD
Phone 010 8319 8277
Email haojunwei@vip.163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-escalation trial. The objective of this study is evaluating safety and preliminary efficacy of intravenous exosomes derived from human induced pluripotent stem cell (GD-iExo-003) in acute ischemic stroke.


Description:

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-escalation trial. This study will consist of 2 parts, with part 1 being a dose-escalation study and part 2 being an expanded safety study based on part 1 findings. A traditional 3+3 dose escalation design will be implemented in part 1. Cohort 1: receive 2×10^9 particles/kg; cohort 2: 4×10^9 particles/kg and cohort 3: 8×10^9 particles/kg. If no dose-limiting toxicities (DLTs) are observed for 2 weeks after administration of the first injection, a new cohort will be enrolled at the next planned dose level. If DLTs are observed in 1 participant in the cohort, another 3 participants will be treated in the same dose level. Dose escalation will be stopped until DLTs are observed in >33% of the participants. In part 2, 20 subjects will be randomized in a 1:1 ratio [exosome (n=10) or exosome placebo (n=10)]. The dose level will be determined by Data Safety Monitoring Board based on part 1.


Recruitment information / eligibility

Status Recruiting
Enrollment 29
Est. completion date August 30, 2025
Est. primary completion date August 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Clinical diagnosis of acute ischemic stroke - Age 18-70 years, inclusion of both genders - Modified Rankin Scale score before stroke of 0-1 - NIHSS score 6-20 at inclusion that did not change by =4 points from screening to baseline assessment. - Time of stroke onset is known and treatment can be started between day 1 and 7 of onset. - Confirmation of hemispheric cortical infarct with magnetic resonance imaging or computed tomography - Subjects who received intravenous thrombolysis or underwent mechanical reperfusion are eligible if they meet all other eligibility criteria. - Adequate hepatic and renal function: serum aspartate aminotransferase =2.5× upper limit of normal; serum alanine aminotransferase =2.5× upper limit of normal; blood urea nitrogen =1.25× upper limit of normal; serum creatinine =1.25× upper limit of normal - Adequate cardiac function. - Subjects or legal representative can sign the informed consent and must be willing and able to comply with all aspects of treatment and follow-up schedule. Exclusion Criteria: - Presence of intracranial hemorrhage on CT including hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage or hemorrhagic transformation, etc. - Presence of a lacunar or a brainstem infarct as the etiology of current symptoms. - Evidence of brain tumor or history of epilepsy or traumatic brain injury. - Subjects with present malignant disease. - Subjects with severe comorbidities including immunodeficiency or coagulation disorders. - Subjects with Alzheimer's disease, Parkinson's disease or other degenerative neurological disease. - Ongoing systemic infection, severe local infection or taking immunosuppressants. - Subjects with negative hepatitis B surface antibody (HBsAg) and positive hepatitis B core antibody (HBcAb), or HBsAg-positive virus carriers, positive hepatitis C antibody, positive syphilis antibody or HIV - Allergy to the study products. - Documented allergies - Participation in any clinical trial in the last 3 months - Inability or unwillingness to comply with the study schedule - Pregnancy, childbearing potential (unless it is certain that pregnancy is not possible), oe breast feeding - Other serious medical or psychiatric illness that is not adequately controlled - Other circumstances that the investigator considers inappropriate for participation in the trial.

Study Design


Intervention

Drug:
exosomes derived from human induced pluripotent stem cell for injection
Exosomes derived from human induced pluripotent stem cell for injection (3.0ml, 1×10^11particles/ml).
a placebo of exosomes derived from human induced pluripotent stem cell for injection
Exosomes placebo, 3.0ml

Locations

Country Name City State
China Xuanwu Hospital, Capital Medical University Beijing

Sponsors (2)

Lead Sponsor Collaborator
Xuanwu Hospital, Beijing Guidon Pharmaceutics Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Change of infarct volume The infarct volume is measured by CT or MRI from the baseline to 14 days 14±2 days
Other Blood marker changes from baseline to discharge A number of blood markers will be examined including C-reactive protein, glial fibrillary acidic protein, IL-1ß, IL-6, IL-8, IL-10, Tumor Necrosis Factor-alpha. at discharge, an average of 14 days
Primary Number of participants who experienced dose-limiting Toxicities (DLTs) DLTs related to exosome is defined as any of the following: (1) Grade 3-4 infusion-related allergic adverse events consisting of perturbation of cardiovascular, respiratory function, or allergic reactions occurring in the first 24h postinfusion of investigational product; (2) grade 3-4 adverse events through seven days after administration of the last injection; (3) neurologic worsening defined as a 4-point increase in NIHSS compared with baseline NIHSS assessed through seven-days after administration of the last injection; and (4) rate of intracranial hemorrhage. Adverse event is graded in Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE 5.0). 14±2 days
Secondary Incidence of severe adverse events The proportion of patients who experienced severe adverse events. 90±7 days
Secondary Favorable functional outcome Rate of favorable functional outcome defined as a modified Rankin Scale (mRS, scores range from 0 to 6, with 0 to 2 indicating favorable outcome and 3 to 6 indicating unfavorable outcome including 6 as death) score of 0-2. 90±7 days
Secondary Functional outcome The range of mRS scores by shift analysis. 90±7 days
Secondary NIHSS score change The change of National Institutes of Health Stroke Scale (NIHSS) score of day 7 to baseline. 7 days
Secondary NIHSS score change The change of National Institutes of Health Stroke Scale (NIHSS) score of day 14 to baseline. 14±2 days
Secondary Quality of Life (EQ-5D-5L) The value of EQ-5D-5L score. 90±7 days
Secondary Barthel Index (BI) The value of BI 90±7 days
See also
  Status Clinical Trial Phase
Recruiting NCT06113848 - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Phase 3
Completed NCT04069546 - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency N/A
Active, not recruiting NCT05700097 - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy Phase 2
Recruiting NCT06058130 - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis N/A
Recruiting NCT04415164 - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke Phase 4
Recruiting NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke Phase 2
Completed NCT05429658 - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System N/A
Recruiting NCT05390580 - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct N/A
Enrolling by invitation NCT05515393 - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke Phase 2
Active, not recruiting NCT05070260 - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo Phase 2/Phase 3
Terminated NCT05547412 - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed NCT03366818 - New Stent Retriever, VERSI System for AIS N/A
Not yet recruiting NCT05293080 - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE Phase 3
Not yet recruiting NCT06437431 - Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy Phase 2/Phase 3
Not yet recruiting NCT06040476 - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS) Phase 2
Completed NCT02223273 - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke) N/A
Completed NCT02586233 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke Phase 1/Phase 2
Terminated NCT01694381 - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor Early Phase 1
Not yet recruiting NCT01594190 - Physical Activity Immediately After Acute Cerebral Ischemia N/A
Completed NCT01120301 - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3) Phase 3